149 related articles for article (PubMed ID: 27191765)
1. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
5. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
7. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
8. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Buendia JA; Bramuglia G; Staatz CE
Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
10. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
13. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
18. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
20. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]